{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:19:43Z","timestamp":1790734783325,"version":"4.1.0"},"reference-count":84,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.ijcha.2024.101543","type":"journal-article","created":{"date-parts":[[2024,10,31]],"date-time":"2024-10-31T08:15:53Z","timestamp":1730362553000},"page":"101543","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Role of Lipoprotein (A) in aortic valve stenosis: Novel disease mechanisms and emerging pharmacotherapeutic approaches"],"prefix":"10.1016","volume":"55","author":[{"given":"Mohammad Ishrak","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raisa Subaita","family":"Zahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel Casso","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1261-5785","authenticated-orcid":false,"given":"Francisco Jos\u00e9","family":"Romeo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12062178","article-title":"The global burden of Valvular heart disease: from clinical epidemiology to management","volume":"12","author":"Santangelo","year":"2023","journal-title":"J. Clin. Med."},{"issue":"1 Suppl","key":"10.1016\/j.ijcha.2024.101543_b0010","first-page":"61","article-title":"Aortic stenosis","volume":"38","author":"Ross","year":"1968","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2024.101543_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2022.783543","article-title":"Uncoupling the vicious cycle of mechanical stress and inflammation in calcific aortic valve disease","volume":"9","author":"Dayawansa","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"issue":"5","key":"10.1016\/j.ijcha.2024.101543_b0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1097\/MOL.0b013e3282a66099","article-title":"Aortic valve stenosis: an active Atheroinflammatory process","volume":"18","author":"Helske","year":"2007","journal-title":"Curr. Opin. Lipidol."},{"issue":"11","key":"10.1016\/j.ijcha.2024.101543_b0025","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1161\/CIRCRESAHA.110.234146","article-title":"Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification","volume":"108","author":"New","year":"2011","journal-title":"Circ. Res."},{"issue":"5","key":"10.1016\/j.ijcha.2024.101543_b0030","first-page":"e35","article-title":"2020 ACC\/AHA guideline for the management of patients with Valvular heart disease: executive summary: a report of the American college of cardiology\/American heart association joint committee on clinical practice guidelines","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.ijcha.2024.101543_b0035","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.thromres.2017.10.027","article-title":"Effects of vitamin K antagonist on aortic valve degeneration in non-valvular atrial fibrillation patients: prospective 4-year observational study","volume":"160","author":"Yamamoto","year":"2017","journal-title":"Thromb. Res."},{"issue":"36","key":"10.1016\/j.ijcha.2024.101543_b0040","doi-asserted-by":"crossref","first-page":"25621","DOI":"10.1016\/S0021-9258(18)35646-1","article-title":"Apolipoprotein B, the major protein component of triglyceride-rich and low density lipoproteins","volume":"267","author":"Chan","year":"1992","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijcha.2024.101543_b0045","doi-asserted-by":"crossref","first-page":"3491764","DOI":"10.1155\/2020\/3491764","article-title":"Lipoprotein(a) the insurgent: a new insight into the structure, function, metabolism, pathogenicity, and medications affecting lipoprotein(a) molecule","volume":"2020","author":"Jawi","year":"2020","journal-title":"J Lipids."},{"issue":"7","key":"10.1016\/j.ijcha.2024.101543_b0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jamacardio.2019.1581","article-title":"Genetic variation in LPA, calcific aortic valve stenosis in patients undergoing cardiac surgery, and familial risk of aortic valve microcalcification","volume":"4","author":"Perrot","year":"2019","journal-title":"JAMA Cardiol."},{"key":"10.1016\/j.ijcha.2024.101543_b0055","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.amjcard.2020.03.043","article-title":"Lipoprotein (a): an update on a marker of residual risk and associated clinical manifestations","volume":"126","author":"Shah","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"41","key":"10.1016\/j.ijcha.2024.101543_b0060","doi-asserted-by":"crossref","first-page":"23914","DOI":"10.1074\/jbc.270.41.23914","article-title":"Site-specific mutagenesis demonstrates that cysteine 4326 of apolipoprotein B is required for covalent linkage with apolipoprotein (a) in vivo","volume":"270","author":"Callow","year":"1995","journal-title":"J. Biol. Chem."},{"issue":"22","key":"10.1016\/j.ijcha.2024.101543_b0065","doi-asserted-by":"crossref","first-page":"10147","DOI":"10.1073\/pnas.92.22.10147","article-title":"Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a)","volume":"92","author":"McCormick","year":"1995","journal-title":"PNAS"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0070","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/CIRCULATIONAHA.113.004406","article-title":"Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin)","volume":"129","author":"Khera","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0075","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.mayocp.2016.04.013","article-title":"My approach to the patient with familial hypercholesterolemia","volume":"91","author":"Safarova","year":"2016","journal-title":"Mayo Clin. Proc."},{"issue":"20","key":"10.1016\/j.ijcha.2024.101543_b0080","doi-asserted-by":"crossref","first-page":"2553","DOI":"10.1016\/j.jacc.2020.03.057","article-title":"Worldwide prevalence of familial hypercholesterolemia: meta-analyses of 11 million subjects","volume":"75","author":"Beheshti","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcha.2024.101543_b0085","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jacc.2022.06.019","article-title":"Ancestry, lipoprotein(a), and cardiovascular risk thresholds: JACC review topic of the week","volume":"80","author":"Tsimikas","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101543_b0090","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur. Heart J."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101543_b0095","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1161\/CIRCULATIONAHA.122.060667","article-title":"Lipoprotein(a) in youth and prediction of major cardiovascular outcomes in adulthood","volume":"147","author":"Raitakari","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ijcha.2024.101543_b0100","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its significance in cardiovascular disease: a review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol."},{"issue":"1484","key":"10.1016\/j.ijcha.2024.101543_b0105","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1098\/rstb.2007.2130","article-title":"Valvulogenesis: the moving target","volume":"362","author":"Butcher","year":"2007","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"1484","key":"10.1016\/j.ijcha.2024.101543_b0110","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1098\/rstb.2007.2125","article-title":"Heart valve macro- and microstructure","volume":"362","author":"Misfeld","year":"2007","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"issue":"9","key":"10.1016\/j.ijcha.2024.101543_b0115","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.006339","article-title":"Valve interstitial cells: the key to understanding the pathophysiology of heart valve calcification","volume":"6","author":"Rutkovskiy","year":"2017","journal-title":"J. Am. Heart Assoc."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101543_b0120","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/cvr\/cvm049","article-title":"Nitric oxide regulates vascular calcification by interfering with TGF- signalling","volume":"77","author":"Kanno","year":"2008","journal-title":"Cardiovasc. Res."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101543_b0125","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/01.mol.0000174155.61307.5f","article-title":"Lipoprotein-associated phospholipase A2 as a target of therapy","volume":"16","author":"Macphee","year":"2005","journal-title":"Curr. Opin. Lipidol."},{"issue":"10","key":"10.1016\/j.ijcha.2024.101543_b0130","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1515\/cclm-2012-0015","article-title":"Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis","volume":"50","author":"Kolasa-Trela","year":"2012","journal-title":"Clin. Chem. Lab. Med."},{"issue":"5","key":"10.1016\/j.ijcha.2024.101543_b0135","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jacc.2013.05.105","article-title":"Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization","volume":"63","author":"Mahmut","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcha.2024.101543_b0140","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jacbts.2020.06.012","article-title":"Interaction of autotaxin with lipoprotein(a) in patients with calcific aortic valve stenosis","volume":"5","author":"Bourgeois","year":"2020","journal-title":"JACC Basic Transl Sci."},{"key":"10.1016\/j.ijcha.2024.101543_b0145","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jss.2017.02.028","article-title":"Lysophosphatidylcholine activates the Akt pathway to upregulate extracellular matrix protein production in human aortic valve cells","volume":"213","author":"Cheng","year":"2017","journal-title":"J. Surg. Res."},{"issue":"7","key":"10.1016\/j.ijcha.2024.101543_b0150","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1586\/erc.11.72","article-title":"Role of 5-lipoxygenase pathway in the pathophysiology of the aortic stenosis","volume":"9","author":"Akdemir","year":"2011","journal-title":"Expert Rev. Cardiovasc. Ther."},{"issue":"12","key":"10.1016\/j.ijcha.2024.101543_b0155","doi-asserted-by":"crossref","DOI":"10.3390\/biom9120760","article-title":"Lipoprotein(a) as orchestrator of calcific aortic valve stenosis","volume":"9","author":"Schnitzler","year":"2019","journal-title":"Biomolecules"},{"issue":"12","key":"10.1016\/j.ijcha.2024.101543_b0160","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol."},{"issue":"5","key":"10.1016\/j.ijcha.2024.101543_b0165","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101543_b0170","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1161\/CIRCRESAHA.118.313864","article-title":"Potential causality and emerging medical therapies for lipoprotein(a) and its associated oxidized phospholipids in calcific aortic valve stenosis","volume":"124","author":"Tsimikas","year":"2019","journal-title":"Circ. Res."},{"issue":"17","key":"10.1016\/j.ijcha.2024.101543_b0175","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"9","key":"10.1016\/j.ijcha.2024.101543_b0180","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/j.jcmg.2023.02.013","article-title":"Association of inflammation and lipoprotein(a) with aortic valve calcification","volume":"16","author":"Marrero","year":"2023","journal-title":"J. Am. Coll. Cardiol. Img."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101543_b0185","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10753-012-9579-6","article-title":"Inflammation is associated with the remodeling of calcific aortic valve disease","volume":"36","author":"Cote","year":"2013","journal-title":"Inflammation"},{"issue":"21","key":"10.1016\/j.ijcha.2024.101543_b0190","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1093\/eurheartj\/eht034","article-title":"Aortic stenosis, atherosclerosis, and skeletal bone: is there a common link with calcification and inflammation?","volume":"34","author":"Dweck","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2024.101543_b0195","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.atherosclerosis.2018.08.029","article-title":"Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease","volume":"277","author":"Cho","year":"2018","journal-title":"Atherosclerosis"},{"issue":"11S","key":"10.1016\/j.ijcha.2024.101543_b0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.18087\/cardio.n328","article-title":"The renin-angiotensin-aldosterone system as a potential target for therapy in patients with calcific aortic stenosis: a literature review","volume":"59","author":"Kostyunin","year":"2019","journal-title":"Kardiologiia"},{"issue":"13","key":"10.1016\/j.ijcha.2024.101543_b0205","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jacc.2006.11.043","article-title":"Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits","volume":"49","author":"Arishiro","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0210","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.jacc.2011.01.063","article-title":"Impact of renin-angiotensin system blockade therapy on outcome in aortic stenosis","volume":"58","author":"Nadir","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101543_b0215","doi-asserted-by":"crossref","first-page":"198","DOI":"10.3109\/01913123.2014.991884","article-title":"HIF-1alpha and VEGF: immunohistochemical profile and possible function in human aortic valve stenosis","volume":"39","author":"Perrotta","year":"2015","journal-title":"Ultrastruct. Pathol."},{"issue":"13","key":"10.1016\/j.ijcha.2024.101543_b0220","doi-asserted-by":"crossref","first-page":"e64","DOI":"10.1093\/eurjpc\/zwad059","article-title":"Interaction between elevated lipoprotein(a) and LDL cholesterol on mortality risk in patients with coronary artery disease","volume":"30","author":"Dykun","year":"2023","journal-title":"Eur. J. Prev. Cardiol."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101543_b0225","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.amjcard.2018.04.046","article-title":"Comparison of lipoprotein(a)-levels in patients >\/=70 years of age with versus without aortic valve stenosis","volume":"122","author":"Mahabadi","year":"2018","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101543_b0230","doi-asserted-by":"crossref","DOI":"10.1001\/jamacardio.2024.1882","article-title":"Lipoprotein(a) and calcific aortic valve stenosis progression a systematic review and meta-analysis","author":"Arsenault","year":"2024","journal-title":"JAMA Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0235","doi-asserted-by":"crossref","first-page":"e016372","DOI":"10.1161\/CIRCIMAGING.123.016372","article-title":"Identifying people at high risk for severe aortic stenosis: aortic valve calcium versus lipoprotein(a) and low-density lipoprotein cholesterol","volume":"17","author":"Marrero","year":"2024","journal-title":"Circ. Cardiovasc. Imaging"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101543_b0240","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11020307","article-title":"Purinergic signaling in pathologic osteogenic differentiation of aortic valve interstitial cells from patients with aortic valve calcification","volume":"11","author":"Klauzen","year":"2023","journal-title":"Biomedicines."},{"key":"10.1016\/j.ijcha.2024.101543_b0245","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yjmcc.2015.03.002","article-title":"Carbonic anhydrase XII in valve interstitial cells promotes the regression of calcific aortic valve stenosis","volume":"82","author":"Bouchareb","year":"2015","journal-title":"J. Mol. Cell. Cardiol."},{"issue":"19","key":"10.1016\/j.ijcha.2024.101543_b0250","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914939","article-title":"Lp(a) in the pathogenesis of aortic stenosis and approach to therapy with antisense oligonucleotides or short interfering RNA","volume":"24","author":"Di Costanzo","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijcha.2024.101543_b0255","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.atherosclerosis.2018.03.025","article-title":"Pathological significance of lipoprotein(a) in aortic valve stenosis","volume":"272","author":"Yu","year":"2018","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101543_b0260","first-page":"H856","article-title":"Discovery of shear- and side-specific mRNAs and miRNAs in human aortic valvular endothelial cells","volume":"301","author":"Holliday","year":"2011","journal-title":"Am. J. Phys. Heart Circ. Phys."},{"key":"10.1016\/j.ijcha.2024.101543_b0265","doi-asserted-by":"crossref","first-page":"25397","DOI":"10.1038\/srep25397","article-title":"Identification of side- and shear-dependent microRNAs regulating porcine aortic valve pathogenesis","volume":"6","author":"Rathan","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijcha.2024.101543_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.gene.2021.145987","article-title":"Exploring potential genes and pathways related to calcific aortic valve disease","volume":"808","author":"Qiao","year":"2022","journal-title":"Gene"},{"key":"10.1016\/j.ijcha.2024.101543_b0275","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): a call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcha.2024.101543_b0280","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.ijcha.2024.101543_b0285","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.atherosclerosis.2022.04.005","article-title":"Lipoprotein(a) and ethnicities","volume":"349","author":"Mehta","year":"2022","journal-title":"Atherosclerosis"},{"issue":"24","key":"10.1016\/j.ijcha.2024.101543_b0290","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/eurheartj\/ehz310","article-title":"Statin therapy increases lipoprotein(a) levels","volume":"41","author":"Tsimikas","year":"2020","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcha.2024.101543_b0295","doi-asserted-by":"crossref","unstructured":"Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, et al. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med. 2014;371(3):203-12.","DOI":"10.1056\/NEJMoa1300955"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101543_b0300","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and benefit of PCSK9 inhibition in patients with nominally controlled LDL cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0305","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jacl.2019.09.010","article-title":"Lipoprotein apheresis for lipoprotein(a) and cardiovascular disease","volume":"13","author":"Moriarty","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"4","key":"10.1016\/j.ijcha.2024.101543_b0310","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11883-019-0773-y","article-title":"Can Lp(a) lowering against background statin therapy really reduce cardiovascular risk?","volume":"21","author":"Reiner","year":"2019","journal-title":"Curr. Atheroscler. Rep."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0315","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An exploratory analysis of proprotein convertase subtilisin\/kexin type 9 inhibition and aortic stenosis in the FOURIER trial","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol."},{"issue":"9","key":"10.1016\/j.ijcha.2024.101543_b0320","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1210\/jc.2016-1206","article-title":"PCSK9 R46L loss-of-function mutation reduces lipoprotein(a), LDL cholesterol, and risk of aortic valve stenosis","volume":"101","author":"Langsted","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.ijcha.2024.101543_b0325","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1161\/ATVBAHA.123.320271","article-title":"Dietary vitamin K(1) intake and incident aortic valve stenosis","volume":"44","author":"Schultz","year":"2024","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"12","key":"10.1016\/j.ijcha.2024.101543_b0330","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA therapeutics to lower blood levels of Lp(a): JACC focus seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcha.2024.101543_b0335","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcha.2024.101543_b0340","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O\u2019Donoghue","year":"2022","journal-title":"Am. Heart J."},{"issue":"17","key":"10.1016\/j.ijcha.2024.101543_b0345","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single ascending dose study of a short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels","volume":"327","author":"Nissen","year":"2022","journal-title":"J. Am. Med. Assoc."},{"issue":"7","key":"10.1016\/j.ijcha.2024.101543_b0350","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s41587-022-01396-x","article-title":"RNA drugs lower lipoprotein(a) and genetically driven cholesterol","volume":"40","author":"Sheridan","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ijcha.2024.101543_b0355","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.omtm.2022.10.009","article-title":"LPA disruption with AAV-CRISPR potently lowers plasma apo(a) in transgenic mouse model: a proof-of-concept study","volume":"27","author":"Doerfler","year":"2022","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"19","key":"10.1016\/j.ijcha.2024.101543_b0360","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.ijcha.2024.101543_b0365","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijcha.2024.101543_b0370","doi-asserted-by":"crossref","first-page":"18810","DOI":"10.1038\/s41598-023-44387-x","article-title":"The effect of immunomodulatory drugs on aortic stenosis: a Mendelian randomisation analysis","volume":"13","author":"Ciofani","year":"2023","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0375","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/CIRCULATIONAHA.109.892224","article-title":"Regular exercise training prevents aortic valve disease in low-density lipoprotein-receptor-deficient mice","volume":"121","author":"Matsumoto","year":"2010","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.ijcha.2024.101543_b0380","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1016\/j.numecd.2020.07.015","article-title":"Association between dietary fiber intake and risk of incident aortic stenosis","volume":"30","author":"Janzi","year":"2020","journal-title":"Nutr Metab Cardiovasc Dis"},{"issue":"39","key":"10.1016\/j.ijcha.2024.101543_b0385","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur. Heart J."},{"issue":"8","key":"10.1016\/j.ijcha.2024.101543_b0390","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian cardiovascular society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcha.2024.101543_b0395","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J. Clin. Lipidol."},{"issue":"24","key":"10.1016\/j.ijcha.2024.101543_b0400","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"issue":"21","key":"10.1016\/j.ijcha.2024.101543_b0405","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1016\/j.jacc.2010.05.050","article-title":"Bisphosphonate use and prevalence of valvular and vascular calcification in women MESA (The Multi-Ethnic Study of Atherosclerosis)","volume":"56","author":"Elmariah","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcha.2024.101543_b0410","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ckj\/sfv146","article-title":"The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials","volume":"9","author":"Caluwe","year":"2016","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ijcha.2024.101543_b0415","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2016.05.022","article-title":"Vitamin K2 regression aortic calcification induced by warfarin via Gas6\/Axl survival pathway in rats","volume":"786","author":"Jiang","year":"2016","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.ijcha.2024.101543_b0420","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.amjcard.2005.05.014","article-title":"Relation of oral anticoagulation to cardiac valvular and coronary calcium assessed by multislice spiral computed tomography","volume":"96","author":"Koos","year":"2005","journal-title":"Am. J. Cardiol."}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724002094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724002094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T01:03:29Z","timestamp":1751245409000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724002094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":84,"alternative-id":["S2352906724002094"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101543","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Lipoprotein (A) in aortic valve stenosis: Novel disease mechanisms and emerging pharmacotherapeutic approaches","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101543","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101543"}}